Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.

NCT02675127 is registered in ClinicalTrials.gov with Genuine Research Center, Egypt as lead sponsor.

NCT NCT02675127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02675127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.
Lead sponsor
Genuine Research Center, Egypt
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2015
Completion date
December 31, 2015
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy